Strong Q3, Improved Guidance Are Signs Takeda Pharmaceutical May Be Undervalued

I last wrote about Takeda Pharmaceutical (NYSE: TAK ) back in early October . I encouraged income investors to take a close look at them because of their better-than-average dividends and relatively affordable prices.I’m Jason Ditz and I have 20 years of experience in foreign policy research. My work has appeared in Forbes, Toronto Star, Minneapolis Star-Tribune, Providence Journal, Washington Times and the Detroit Free Press, as well as American Conservative Magazine and the Quincy Institute for Responsibl ...